Thursday, April 28, 2016 Last update: 6:33 PM
FreshNews.com - COMING SOON! New Features/Design as we Expand our Coverage Globally

Regulus Therapeutics Inc.

News articles for Regulus Therapeutics Inc.:

Tuesday, April 26, 2016

Friday, April 15, 2016

Wednesday, March 16, 2016

Monday, February 22, 2016

Wednesday, February 17, 2016

Thursday, January 21, 2016

  • Regulus Completes RG-101 Enrollment in Phase II Combination Study
    LA JOLLA, Calif., Jan. 21, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced key 2016 programmatic goals to advance RG-101, Regulus' wholly-owned therapy for the treatment of HCV. RG-101 is a GalNAc-conjugated anti-miR targeting ... read more

Wednesday, January 6, 2016

  • Regulus Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    LA JOLLA, Calif., Jan. 6, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the grant of an inducement stock option to Joseph P. "Jay" Hagan on January 4, 2016 in connection with his ... read more

Friday, December 18, 2015

Monday, December 7, 2015

  • Regulus Appoints Joseph P. Hagan Chief Operating Officer
    LA JOLLA, Calif., Dec. 7, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that Joseph P. "Jay" Hagan has been appointed Chief Operating Officer effective January 4, 2016. Mr. Hagan has also been ... read more

Thursday, November 12, 2015

  • Regulus Announces Grant of Patents Covering Lead microRNA Therapeutics
    LA JOLLA, Calif., Nov. 12, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that the U.S. Patent and Trademark Office ("USPTO") has granted patents related to Regulus' most advanced microRNA therapeutics, RG-101, the company's wholly-owned, ... read more

Thursday, November 5, 2015

  • Regulus Reports Third Quarter 2015 Financial Results and Recent Highlights
    LA JOLLA, Calif., Nov. 5, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended September 30, 2015 and provided a summary of recent corporate highlights. http://photos.prnewswire.com/prnvar/20150130/172637LOGO "Regulus' recent achievements reflect our ... read more

Tuesday, November 3, 2015